Sysmex (OTCMKTS:SSMXY) Sees Strong Trading Volume – What’s Next?

Sysmex Corporation ADR (OTCMKTS:SSMXY) shares saw unusually-high trading volume on Monday . Approximately 1,025,127 shares were traded during mid-day trading, an increase of 478% from the previous session’s volume of 177,212 shares.The stock last traded at $9.96 and had previously closed at $9.84.

Wall Street Analysts Forecast Growth

Separately, The Goldman Sachs Group raised shares of Sysmex from a “hold” rating to a “buy” rating in a research report on Thursday, October 9th. One investment analyst has rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, Sysmex has an average rating of “Moderate Buy”.

Sysmex Price Performance

The stock has a market cap of $6.24 billion, a price-to-earnings ratio of 19.83 and a beta of 1.13. The company has a current ratio of 3.34, a quick ratio of 2.49 and a debt-to-equity ratio of 0.11. The company’s fifty day moving average is $10.01 and its two-hundred day moving average is $12.77.

Sysmex (OTCMKTS:SSMXY) last released its quarterly earnings results on Wednesday, November 5th. The company reported $0.16 EPS for the quarter, hitting the consensus estimate of $0.16. The business had revenue of $826.60 million during the quarter, compared to analyst estimates of $880.80 million. Sysmex had a return on equity of 9.86% and a net margin of 9.32%. As a group, research analysts predict that Sysmex Corporation ADR will post 0.57 earnings per share for the current year.

About Sysmex

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.